Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Simple item page
dc.contributor.authorGürbüz M.
dc.contributor.authorKutlu Y.
dc.contributor.authorAkkuş E.
dc.contributor.authorKöksoy E.B.
dc.contributor.authorKöse N.
dc.contributor.authorÖven B.B.
dc.contributor.authorUluç B.O.
dc.contributor.authorDemiray A.G.
dc.contributor.authorErdem D.
dc.contributor.authorDemir B.
dc.contributor.authorTurhal N.S.
dc.contributor.authorÜskent N.
dc.contributor.authorAkbaş S.
dc.contributor.authorSelçukbiricik F.
dc.contributor.authorİnal A.
dc.contributor.authorBilici A.
dc.contributor.authorÖlmez Ö.F.
dc.contributor.authorÇabuk D.
dc.contributor.authorÜnal Ç.
dc.contributor.authorHızal M.
dc.contributor.authorŞendur M.A.N.
dc.contributor.authorKorkmaz M.
dc.contributor.authorKaradurmuş N.
dc.contributor.authorErtürk İ.
dc.contributor.authorGöksu S.S.
dc.contributor.authorTatlı A.M.
dc.contributor.authorGüven D.C.
dc.contributor.authorKılıçkap S.
dc.contributor.authorPaksoy N.
dc.contributor.authorAydıner A.
dc.contributor.authorÇınkır H.Y.
dc.contributor.authorÖzkul Ö.
dc.contributor.authorÖztürk A.
dc.contributor.authorBallı S.
dc.contributor.authorKemal Y.
dc.contributor.authorErdoğan A.P.
dc.contributor.authorEr Ö.
dc.contributor.authorYumuk P.F.
dc.contributor.authorDemirkazık A.
dc.date.accessioned2024-07-22T08:03:46Z
dc.date.available2024-07-22T08:03:46Z
dc.date.issued2022
dc.description.abstractPurpose: Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods: This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results: A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion: This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
dc.identifier.DOI-ID10.1007/s00432-022-04087-x
dc.identifier.issn01715216
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12436
dc.language.isoEnglish
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectSmall Cell Lung Carcinoma
dc.subjectalanine aminotransferase
dc.subjectaspartate aminotransferase
dc.subjectatezolizumab
dc.subjectcarboplatin
dc.subjectcisplatin
dc.subjectetoposide
dc.subjectprogrammed death 1 ligand 1
dc.subjectantineoplastic agent
dc.subjectatezolizumab
dc.subjectmonoclonal antibody
dc.subjectadult
dc.subjectaged
dc.subjectalanine aminotransferase blood level
dc.subjectalopecia
dc.subjectanemia
dc.subjectanorexia
dc.subjectArticle
dc.subjectaspartate aminotransferase blood level
dc.subjectcancer combination chemotherapy
dc.subjectcancer immunotherapy
dc.subjectcancer radiotherapy
dc.subjectconstipation
dc.subjectdiarrhea
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug withdrawal
dc.subjectECOG Performance Status
dc.subjectfatigue
dc.subjectfebrile neutropenia
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjecthypertransaminasemia
dc.subjecthypothyroidism
dc.subjectinduction chemotherapy
dc.subjectinfusion related reaction
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedian survival time
dc.subjectmulticenter study (topic)
dc.subjectmultiple cycle treatment
dc.subjectnausea
dc.subjectneutropenia
dc.subjectoverall survival
dc.subjectpneumonia
dc.subjectprogression free survival
dc.subjectrash
dc.subjectresponse evaluation criteria in solid tumors
dc.subjectretrospective study
dc.subjectsmall cell lung cancer
dc.subjectsmoking
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.subjectvomiting
dc.subjectclinical trial
dc.subjectlung tumor
dc.subjectmulticenter study
dc.subjectpathology
dc.subjectsmall cell lung cancer
dc.titleAtezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
dc.typeArticle

Files

Collections

Scopus Koleksiyonu